A matched cohort study in wound care pairs patients who received a given product or intervention with clinically similar controls, matched on wound type, size, duration, and comorbidity burden, to estimate comparative effectiveness without running a randomized trial. For manufacturers facing payer pushback on a CTP or CAMP, or regulatory teams working through an EU MDR post-market clinical follow-up (PMCF) plan or an FDA postmarket study requirement, this is often the only feasible way to generate comparative evidence at scale. The method has real statistical rigor behind it, and it also has real ways to fail. Whether a matched cohort analysis survives a payer’s medical policy review, an FDA post-market inquiry, or peer review depends on choices made before a single outcome is calculated: which covariates were selected, how matching was executed, and how transparently the residual imbalance was reported.
This article walks through what “matched” actually means methodologically, why the design has become the default in wound care research instead of an RCT, how to build one from real-world data, where these studies typically break down, and how a multi-setting dataset changes what’s feasible.
What Makes a Cohort “Matched” in Wound Care Research?
Matching is a deliberate statistical step that happens before outcomes are examined, not a label applied after the fact to two convenient data pulls. There are two dominant approaches. Exact matching pairs patients on discrete categorical variables (same wound etiology, same Wagner grade for DFUs, same care setting) and works well when the covariate list is short and the dataset is large enough to find pairs. Propensity score matching instead estimates each patient’s probability of receiving the treatment of interest based on a set of baseline covariates, then matches patients on that single composite score. Propensity matching handles a longer covariate list without the exponential pair-finding problem that exact matching runs into once you add more than three or four variables.
In wound care specifically, the covariates that tend to drive outcome differences, and therefore need to be balanced, include baseline wound area and duration, etiology (DFU versus VLU versus pressure injury), depth or staging, and a cluster of comorbidities that materially affect healing trajectory: peripheral arterial disease, glycemic control in diabetic patients, and chronic kidney disease. Care setting matters too. A DFU treated in a hospital-based wound center with weekly sharp debridement and offloading compliance checks is not clinically comparable to the same wound type managed through intermittent home health visits, even if every other baseline variable matches.
The distinction that separates a matched cohort from an ordinary retrospective comparison is that matching forces the two groups into structural comparability before any effectiveness claim is made. A simple retrospective comparison, pulling all patients who used Product A and all patients who used Product B from a database and comparing healing rates, carries whatever confounding existed in how those patients were selected for treatment in the first place. Matching does not eliminate confounding, but it addresses the confounding that is measured and included in the covariate set, which is why covariate selection is the single most consequential decision in the entire design.
Why Are Matched Cohort Studies Used Instead of RCTs in This Space?
Randomized trials in wound care are slow and expensive relative to the commercial and regulatory timelines manufacturers actually work under. A DFU or VLU RCT with adequate power to detect a meaningful difference in complete wound closure typically needs enrollment periods measured in years, and for a niche CTP or CAMP competing against a crowded field of similar products, recruiting enough patients to detect a modest but commercially relevant effect size is often impractical. The trials that do get run also tend to enroll patients who look little like a typical wound clinic population; analyses of U.S. Wound Registry data found that most real-world wound patients would have been excluded from the major wound care RCTs. Matched cohort studies let manufacturers use real-world data that already exists (product utilization records, wound measurements, and claims data) rather than waiting on prospective enrollment.
The regulatory backdrop for this shift is FDA’s 2018 “Framework for FDA’s Real-World Evidence Program,” which laid out how real-world data and real-world evidence, including well-designed observational comparisons, can support regulatory decision-making for drugs and biologics. For medical devices, including the many CTPs cleared through 510(k) or approved through PMA, the controlling document is CDRH’s guidance “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” first issued in 2017 and replaced by an expanded final version in December 2025. That guidance did not replace the evidentiary bar for premarket approval, but it did formalize the pathway by which observational comparative studies, matched cohorts among them, can factor into postmarket obligations and some regulatory submissions. Regulatory teams should still confirm the current version before citing it in a submission, since RWE guidance has continued to evolve.
In practice, matched cohort studies serve two distinct commercial and regulatory functions. The first is generating comparative effectiveness evidence for market access and payer conversations, where a MAC or commercial payer’s medical policy is skeptical of a product’s value relative to standard of care or a competing CTP. The second is supporting post-market obligations, such as PMCF under the EU Medical Device Regulation or FDA Section 522 postmarket surveillance studies in the U.S., without funding a new prospective trial, using existing real-world utilization and outcomes data instead. Both uses depend entirely on the credibility of the matching, which is why payers and regulators scrutinize covariate selection and balance reporting rather than taking the headline effectiveness number at face value.
How Do You Build a Defensible Matched Cohort From Real-World Data?
The sequence matters as much as the technique. First, define the index event, the specific point at which a patient enters the treatment cohort, typically first application of the product or first date of the intervention being studied. Second, specify inclusion and exclusion criteria before touching outcomes data: wound type, minimum follow-up duration, and any washout period to exclude patients with recent prior treatment that would confound the comparison. Third, select covariates for matching based on clinical reasoning and prior literature, not by scanning the dataset for whatever variables happen to predict the outcome. Only after these three steps are locked should matching itself run, either 1:1 or 1:many depending on how much control population is available relative to the treatment cohort.
The data requirements behind this sequence are substantial. A credible matched cohort needs longitudinal wound measurements taken at consistent intervals, not just a baseline and a final visit; product utilization records specific enough to confirm what was actually applied and when; and setting-of-care detail, because a patient managed in a skilled nursing facility generates a different visit cadence and documentation pattern than one seen in a hospital-based wound center or through home health visits. Single-EHR or single-site datasets frequently lack the patient volume to support matching on more than two or three covariates simultaneously, and they almost never capture the setting-of-care variation needed to test whether an effect holds across delivery contexts.
This is the practical argument for pulling matched cohorts from a dataset that spans care settings rather than one confined to a single provider network. Intellicure Analytics’ real-world dataset covers patients treated across SNFs, home health visits, and hospital-based wound centers, which means a matched cohort can be built within a single setting to control for care-delivery variation, or deliberately across settings when the research question is whether a product’s effectiveness holds regardless of where it’s administered. A single-site chart review can’t offer that choice; it only has one setting to work with, and any comparative claim it produces is implicitly limited to that context whether or not the study says so.
What Mistakes Make a Matched Cohort Study Fall Apart?
The most common failure is residual confounding from variables that were never measured in the first place. Matching on demographics, wound etiology, and comorbidity burden does nothing to control for debridement frequency, offloading or compression adherence, or the intensity of nutritional support a patient received, all of which independently affect healing trajectories in DFU and VLU populations. If those process-of-care variables aren’t in the dataset, they can’t be matched on, and any effectiveness difference between cohorts may simply reflect who received more aggressive concurrent care rather than a true product effect. Reviewers who understand wound care will ask about this directly.
A second failure is running out of statistical power after matching. Propensity score matching often discards a meaningful share of the original sample because usable matches don’t exist for every treated patient, and a study that started with what looked like an adequate cohort can end up underpowered to detect anything but a large effect. Credible matched cohort reporting discloses the match rate, how many treated patients were dropped for lack of a suitable control, and post-match balance diagnostics, typically standardized mean differences for each covariate, showing that the matched groups are actually comparable and not just superficially similar. A study that reports only the headline outcome comparison without these diagnostics should be read with skepticism.
The third and most easily overlooked failure is selection bias introduced by restricting the analysis to patients with complete follow-up. Dropping patients who were lost to follow-up, switched products mid-course, or had wounds that failed to close and were referred elsewhere systematically removes non-responders from the analysis, which inflates the apparent effectiveness of whichever product retained more of its patient population through to a documented endpoint. This bias is subtle because it looks like a data-quality decision rather than a methodological one, but its effect on the result can be larger than the matching itself.
How Does Intellicure Analytics Support Matched Cohort Study Design?
Intellicure Analytics’ Wound Care Industry Dashboard aggregates real-world data on product utilization, wound type, and care setting at a scale that supports the covariate selection matched cohort studies depend on. Because the underlying dataset spans CTPs (also called CAMPs) and multiple wound etiologies across SNFs, home visits, and hospital-based wound centers, it gives researchers a matchable population large enough to hold several covariates constant simultaneously, something a single-site or single-payer dataset typically cannot do.
The delivery mechanism for this work sits within Intellicure’s Comparative Effectiveness Studies and PMCF services. A manufacturer or research team brings a specific hypothesis, for example, a comparative effectiveness question about a CTP relative to a named class of competitors in DFU management, and Intellicure builds the matched cohort against that hypothesis, applying the covariate selection, matching ratio, and balance diagnostics the design calls for, then reports the standardized mean differences and match rates alongside the outcome comparison rather than presenting the headline result in isolation.
It’s worth stating plainly what this kind of engagement can and cannot deliver. It supports observational matching, comparative trend analysis, and PMCF-grade real-world evidence generation. It does not substitute for randomization, and it does not produce causal proof equivalent to a well-powered RCT. Any manufacturer using matched cohort output for a regulatory submission or a payer negotiation should treat it as one component of an evidence package, reviewed against the specific regulatory or contractual bar it needs to meet, rather than as a standalone substitute for that bar.
A matched cohort study is only as credible as its covariate selection and its balance reporting. The headline effectiveness number means little if the matching methodology, the match rate, and the standardized mean differences behind it aren’t disclosed alongside it, and reviewers at payers, MACs, and regulatory bodies increasingly know to ask for that detail before accepting the conclusion. Building that kind of study from a single-site chart review usually means starting with too few patients and too narrow a care setting to support the covariate list the question actually requires. Learn more about our services to see how Intellicure Analytics’ Comparative Effectiveness Studies and PMCF services build matched cohorts from real-world wound care data spanning multiple care settings, with the balance diagnostics documented from the start.